I think it will be limited because the partnership was so short
Frstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function
Findings of the prespecified analysis of the trial, published in The Lancet, suggest that semaglutide and possibly other glucagon-like peptide-1 receptor agonists (GLP-1Ras) should be reconceptualised as disease-modifying treatments rather than solely medications for glycaemic control or weight loss, the studys authors have suggested
This one is easily the best I've ever tasted
Device + molecule integration A key differentiator in Sandozs approach is the integration of an internally developed autoinjector platform, combining: - small-molecule and biologics expertise - advanced device engineering capabilities - biosimilar development know-how This strategy aims to ensure both therapeutic equivalence and user-friendly administration
Counter-regulatory responses to postprandial hypoglycaemia in patients with post-bariatric hypoglycaemia vs surgical and non-surgical control individuals